NO964330L - Farmasöytisk sammensetning for terapeutisk behandling av tardiv dyskinesi og anvendelse derav - Google Patents

Farmasöytisk sammensetning for terapeutisk behandling av tardiv dyskinesi og anvendelse derav

Info

Publication number
NO964330L
NO964330L NO964330A NO964330A NO964330L NO 964330 L NO964330 L NO 964330L NO 964330 A NO964330 A NO 964330A NO 964330 A NO964330 A NO 964330A NO 964330 L NO964330 L NO 964330L
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
therapeutic treatment
tardive dyskinesia
tardive
dyskinesia
Prior art date
Application number
NO964330A
Other languages
English (en)
Other versions
NO964330D0 (no
Inventor
Masaomi Iyo
Hajime Sasaki
Yohko Maeda
Kenji Hashimoto
Toshiya Inada
Yoshie Kitao
Original Assignee
Masaomi Iyo
Meiji Seika Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Masaomi Iyo, Meiji Seika Kaisha filed Critical Masaomi Iyo
Publication of NO964330D0 publication Critical patent/NO964330D0/no
Publication of NO964330L publication Critical patent/NO964330L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
NO964330A 1994-04-15 1996-10-11 Farmasöytisk sammensetning for terapeutisk behandling av tardiv dyskinesi og anvendelse derav NO964330L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP7714694 1994-04-15
PCT/JP1995/000736 WO1995028177A1 (en) 1994-04-15 1995-04-14 Medicinal composition for treating tardive dyskinesia and utilization thereof

Publications (2)

Publication Number Publication Date
NO964330D0 NO964330D0 (no) 1996-10-11
NO964330L true NO964330L (no) 1996-10-11

Family

ID=13625663

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964330A NO964330L (no) 1994-04-15 1996-10-11 Farmasöytisk sammensetning for terapeutisk behandling av tardiv dyskinesi og anvendelse derav

Country Status (8)

Country Link
US (1) US5712282A (no)
EP (1) EP0755685A4 (no)
JP (1) JP3598116B2 (no)
AU (1) AU2224195A (no)
CA (1) CA2187086A1 (no)
FI (1) FI964113L (no)
NO (1) NO964330L (no)
WO (1) WO1995028177A1 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099003A1 (en) 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
US6268352B1 (en) * 1998-09-02 2001-07-31 The Regents Of The University Of California Promoters of neural regeneration
WO2001032170A1 (en) 1999-09-13 2001-05-10 Swope David M Composition and method for decreasing neurologic symptomatology
EP1343528A2 (en) * 2000-11-02 2003-09-17 Research Foundation of City University of New York Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4
IL149106A0 (en) * 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors
WO2003056899A2 (en) * 2002-01-04 2003-07-17 Henry Ford Health System Nitric oxide donors for treatment of disease and injury
EP1541149A1 (en) * 2002-06-26 2005-06-15 Kyowa Hakko Kogyo Co., Ltd. Phosphodiesterase inhibitor
WO2006091542A2 (en) * 2005-02-22 2006-08-31 Cedars-Sinai Medical Center Use of sildenafil, vardenafil and other 5-phosphodiesterase inhibitors to enhance permeability of the abnormal blood-brain barrier

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59148748A (ja) * 1983-02-10 1984-08-25 Takeda Chem Ind Ltd ノナペプチド
HU201906B (en) * 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
JP2578001B2 (ja) * 1989-12-11 1997-02-05 明治製菓株式会社 抗痴呆薬

Also Published As

Publication number Publication date
FI964113A0 (fi) 1996-10-14
NO964330D0 (no) 1996-10-11
EP0755685A4 (en) 2000-05-03
WO1995028177A1 (en) 1995-10-26
AU2224195A (en) 1995-11-10
FI964113A7 (fi) 1996-10-14
CA2187086A1 (en) 1995-10-26
EP0755685A1 (en) 1997-01-29
FI964113L (fi) 1996-10-14
JP3598116B2 (ja) 2004-12-08
US5712282A (en) 1998-01-27

Similar Documents

Publication Publication Date Title
NO994778D0 (no) FremgangsmÕter og sammensetninger for behandling av tarmbetennelse
BR9407799A (pt) Composição de matéria método de tratamento e composição farmaceutica
NO972125D0 (no) Hemmoroideblandinger og fremgangsmåte for anvendelse
PL312064A1 (en) Soft gelatinous form of pharmaceutical dose
FI963252A7 (fi) Kivun hoitoon tarkoitetut uudet opioidipeptidit ja niiden käyttö
NO994014L (no) Arylsulfonamider og analoger derav og deres anvendelse for behandling av neurodegenerative sykdommer
FI941826A0 (fi) Menetelmät ja koostumukset elimen hypofunktion ennaltaehkäisemiseksi ja/tai terapeuttiseksi hoitamiseksi
NO971015L (no) Forbindelser og metoder for behandling av cancer
FI953479A0 (fi) 1-aryylipyrimidiinijohdannaiset ja niiden farmaseuttinen käyttö
NO943511D0 (no) Farmasöytiske preparater og anvendelse derav
DK0862431T3 (da) Anvendelse af pædiatrisk farmaceutisk formulering omfattende amoxycillin og clavulanat
EE9800234A (et) Ravimeetod ja farmatseutiline kompositsioon
HUP9902655A3 (en) Pharmaceutical composition of hedgehog proteins and use thereof
NO971900D0 (no) Blandinger og behandling av multippel sklerose
FI971364L (fi) Kolkisiinijohdannaiset ja niiden terapeuttinen käyttö
DE69620691D1 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
PT932400E (pt) Derivados de anticonvulsionantes uteis no tratamento da dor neuropatica
NO964330L (no) Farmasöytisk sammensetning for terapeutisk behandling av tardiv dyskinesi og anvendelse derav
NO952568D0 (no) Behandling av cellulosemateriale og blandinger for anvendelse for dette
IL121329A (en) Pharmaceutical composition for the treatment of cancer comprising somatostatin2 and other peptides
FI956353L (fi) Farmaseuttiset valmisteet ja niiden käyttö etenkin neurodegeneratiivisten sairauksien hoidossa
DK0670721T3 (da) Lægemiddel til behandling og forebyggelse af knogle- og ledsygdomme
FI961494L (fi) Farmaseuttisia koostumuksia ja niiden käyttö, etenkin hermoston rappeutumissairauksien hoitamiseksi
FI974609A7 (fi) Uusia heterosyklisiä yhdisteitä kivun hoitoon ja niiden käyttö
NO962782L (no) Farmasöytiske formuleringer omfattende polytiourea, og metode for anvendelse derav

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application